natgillin/translations-raw huggingface dataset:
In the absence of specific data concerning transmission of resistant bacteria from rabbits to humans, the risk analysis from other animal species where enrofloxacin is used (poultry and pigs) is extrapolated to rabbits. 
Ker ni posebnih podatkov glede prenosa odpornih bakterij s kuncev na človeka, je analiza tveganja za druge živalske vrste, pri katerih se uporablja enrofloksacin (perutnina in prašiči), ekstrapolirana za kunce.
This observed decrease of susceptibility could either be explained by methodological factors, or it could reflect a true emergence of decreased susceptibility, that could be related to the use of enrofloxacin in rabbits or other animal species. 
To opaženo zmanjšanje občutljivosti je mogoče razložiti z metodološkimi dejavniki, lahko pa je tudi posledica dejanskega pojava zmanjšane občutljivosti, ki je morda povezana z uporabo enrofloksacina pri kuncih ali drugih živalskih vrstah.
The transfer of resistant bacteria from animals to humans may occur via consumption of meat carrying enteric zoonotic bacteria e.g. E. coli or by direct contact with animals, e.g. Staph. 
Prenos odpornih bakterij z živali na ljudi se lahko zgodi z zaužitjem mesa, ki vsebuje enterične zoonotske bakterije, na primer E. Coli, ali z neposrednim stikom z živalmi, na primer Staph.
The prudent use recommendations and warnings that are listed in the product information for these products should be strictly followed and the products should not be used as a first line treatment. 
Priporočila za preudarno uporabo in opozorila o taki uporabi, ki so navedena v informacijah o zdravilu za zadevna zdravila, je treba strogo upoštevati, saj se ta zdravila ne smejo uporabljati za začetno zdravljenje.
SP VETERINARIA Ctra.Reus-Vinyols, Km, 43330 Ruidoms SPAIN 
SP VETERINARIA Ctra.Reus-Vinyols, Km, 43330 Ruidoms ŠPANIJA
On 30 September 2011, France initiated a referral under Article 35 of Directive 2001/82/EC, as amended, for the veterinary medicinal product HIPRALONA ENRO-S and its generics indicated for use in rabbits. 
Francija je 30. septembra 2011 skladno s členom 35 Direktive 2001/82/ES, kakor je bila spremenjena, sprožila postopek napotitve za zdravilo HIPRALONA ENRO-S za uporabo v veterinarski medicini in njegova generična zdravila za uporabo pri kuncih.
The enrofloxacin is an antimicrobial belonging to the class of fluoroquinolones, which are listed by the WHO as a critically important class of antimicrobials for human health (Critically important antimicrobials for human medicine, WHO/AGISAR, Copenhagen, 2009). 
Enrofloksacin je protimikrobno zdravilo iz razreda fluorokinolonov, ki jih SZO uvršča v zelo pomemben razred protimikrobnih zdravil za človekovo zdravje (protimikrobna sredstva, ki so bistvenega pomena za humano medicino, SZO/AGISAR, København, 2009).
There are two risks for public health identified with the use of enrofloxacin in rabbits: (i) the risk for spread of methicillin resistant Staphylococcus aureus (MRSA) from rabbits to people in contact with these animals and (ii) the risk of spread of resistant zoonotic bacteria and transmissible resistance genes via food, e.g. Salmonella and E. coli. 
Pri uporabi enrofloksacina pri kuncih sta bili opredeljeni dve tveganji za javno zdravje: (i) tveganje za širjenje proti meticilinu odpornega Staphylococcus aureus (MRSA) s kuncev na ljudi ob stiku z živalmi in (ii) tveganje za širjenje odpornih zoonotskih bakterij in prenosljivih genov za odpornost s hrano, na primer salmonele in E. coli.
From the route of administration it can be concluded that the risk of rabbit treatment would be similar to that of poultry. 
Na podlagi načina uporabe zdravila je mogoče sklepati, da bo tveganje pri zdravljenju kuncev podobno tveganju pri zdravljenju perutnine.
The safety and efficacy of the product have been demonstrated in a well conducted GCP compliant trial that fulfils the requirements of Directive 2001/82/EC and the relevant guidelines using a dose of 10 mg/kg bw for 5 consecutive days. 
Varnost in učinkovitost zdravila sta bili dokazani v preskušanju, ustrezno izvedenem v skladu z dobro klinično prakso, zahtevami Direktive 2001/82/ES in ustreznimi smernicami, pri čemer je bil uporabljen odmerek 10 mg/kg telesne mase 5 zaporednih dni.
• on the basis of the available data on antimicrobial resistance, and taking into account the very limited data on resistance that are available in rabbit production, the CVMP considered that the use of the concerned products in rabbits would not represent a higher risk for public health when compared with use in other animals species; 
• je odbor CVMP na podlagi razpoložljivih podatkov o protimikrobni odpornosti in ob upoštevanju zelo omejenih podatkov o odpornosti, ki so na voljo za rejo kuncev, menil, da uporaba zadevnih zdravil pri kuncih ne pomeni večjega tveganja za javno zdravje v primerjavi z uporabo pri drugih živalskih vrstah;
The products are authorised for use in the target species chickens, turkeys and rabbits. 
Zdravila se lahko uporabljajo pri ciljnih vrstah piščancev, puranov in kuncev.
• Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. 
• fluorokinolone je treba uporabljati le za zdravljenje kliničnih stanj, pri katerih je bil odziv na druge razrede protimikrobnih zdravil slab ali se v zvezi z njimi pričakuje, da bo slab;
A less well characterised and possibly slightly higher risk as compared to other species could be acceptable in case of a minor species. 
Za manj pomembne vrste bi lahko bilo v primerjavi z drugimi živalskimi vrstami sprejemljivo slabše opredeljeno in nekoliko večje tveganje.
The development of antimicrobial resistance is a risk for target animal species resulting in lack of efficacious treatment and for humans by transferring resistant bacteria from animals to humans. 
Razvoj protimikrobne odpornosti je tveganje za ciljno živalsko vrsto, kar povzroči nezadostno učinkovito zdravljenje, in ljudi, saj se odporne bakterije z živali prenašajo na ljudi.
Regarding S. aureus, 89% (2009) and 82% (2010) of the bacterial isolates were susceptible to enrofloxacin. 
Pri S. aureus je bilo za enrofloksacin občutljivih 89 % (2009) in 82 % (2010) bakterijskih izolatov.
Furthermore, several studies were presented in order to address the susceptibility of different field strains of P. multocida to enrofloxacin. 
Poleg tega je bilo predloženih več študij, ki so obravnavale občutljivost različnih sevov P. multocida za enrofloksacin.
Risk to animals health 
Tveganje za zdravje živali
Taking into account all available data it was considered that the use of HIPRALONA ENRO-S and its generics in rabbits would represent a comparable or lower risk for public health compared to the use of enrofloxacin in other animal species (e.g. poultry or pigs). 
Na podlagi vseh razpoložljivih podatkov se je štelo, da uporaba zdravila HIPRALONA ENRO-S in njegovih generičnih zdravil pri kuncih ne pomeni primerljivega ali manjšega tveganja za javno zdravje v primerjavi z uporabo enrofloksacina pri drugih živalskih vrstah (npr. perutnini ali prašičih).
The efficacy of the product has been demonstrated in a well conducted GCP compliant trial. 
Učinkovitost zdravila je bila dokazana v preskušanju, ki je bilo ustrezno izvedeno v skladu z dobro klinično prakso.
The pharmaceutical form is an oral solution administered via the drinking water. 
Farmacevtska oblika je peroralna raztopina, ki se daje s pitno vodo.
The data from published literature (RESAPATH annual reports) show that the sensitivity of P. multocida strains to enrofloxacin in rabbits was high (100% and 99% in 2009 and 2010, respectively). 
Podatki iz objavljene literature (letna poročila mreže RESAPATH) kažejo, da je občutljivost sevov P. multocida za enrofloksacin pri kuncih velika (100 % leta 2009 in 99 % leta 2010).
With regard to intensively reared rabbits, the risk is likely to be minor in comparison with the other species due to the size of rabbits production and no measures have been deemed necessary to minimise the risk for spread of MRSA from those. 
Pri kuncih iz intenzivne reje je tveganje zaradi obsega reje kuncev verjetno majhno v primerjavi z drugimi vrstami, zato se je štelo, da niso potrebni nobeni ukrepi za zmanjševanje tveganja za širjenje MRSE pri teh živalih.
1 CVMP Public statement on the use of (fluoro)quinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health (2007) (EMEA/CVMP/SAGAM/184651/2005)http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/10/WC500005152.pdf 
1 CVMP - Javno sporočilo o uporabi (fluoro)kinolonov pri živalih za proizvodnjo živil v Evropski uniji: razvoj odpornosti in vpliv na zdravje ljudi in živali (2007) (EMEA/CVMP/SAGAM/184651/2005)http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/10/WC500005152.pdf
It is acknowledged that the limited availability of authorised veterinary medicinal products containing first line antimicrobials as active substance make it difficult to comply with the responsible use recommendations for fluoroquinolones and the recommendation that it is desirable that antimicrobials 
Znano je, da je zaradi omejene razpoložljivosti odobrenih zdravil za uporabo v veterinarski medicini, ki kot zdravilno učinkovino vsebujejo protimikrobne učinkovine prve izbire, težavno delovati skladno s priporočili za odgovorno uporabo fluorokinolonov in priporočilom, naj se namesto fluorokinolonov kot zdravljenje
Nutrição e Comércio de Produtos Químicos 
Portugalska Prodivet-Zn, Nutrição e Comércio de Produtos Químicos
HIPRALONA ENRO-S and its generics were involved in the referral under Article 35 of Directive 2001/82/EC for all veterinary medicinal products containing quinolones including fluoroquinolones intended for use in food-producing species (EMEA/V/A/049) and the adequate prudent use warnings were recommended for these products. 
Zdravilo HIPRALONA ENRO-S in njegova generična zdravila so bila predmet postopka napotitve iz člena 35 Direktive 2001/82/ES za vsa zdravila za uporabo v veterinarski medicini, ki vsebujejo kinolone, vključno s fluorokinoloni, namenjena uporabi pri živalskih vrstah za proizvodnjo živil (EMEA/V/A/049), in priporočena so bila ustrezna opozorila za preudarno uporabo teh zdravil.
08028 - BARCELONA SPAIN 
08028 - BARCELONA ŠPANIJA
In intensive reared rabbits the treatment will be of the flock and not individual animals which may increase the risk of development of resistant bacteria, this is similar to poultry production where flocks of animals are treated. 
Pri kuncih iz intenzivne reje se zdravi cela kletka in ne posamezne živali, kar lahko poveča tveganje za razvoj odpornih bakterij; podobno je pri reji perutnine, kjer se zdravijo jate živali.
From the RESAPATH annual reports, the highest susceptibility levels to enrofloxacin in E. coli in rabbits were 90% (2009) and 85% (2010). 
V letnih poročilih mreže RESAPATH sta najvišji ravni občutljivosti E. coli za enrofloksacin pri kuncih znašali 90 % (2009) in 85 % (2010).
The concerns raised by France were that the use of HIPRALONA ENRO-S and its generics in rabbit production would increase Escherichia coli and Staphylococcus aureus resistance to enrofloxacin. 
Francija je izrazila zaskrbljenost, da bi lahko uporaba zdravila HIPRALONA ENRO-S in njegovih generičnih zdravil pri kunčjereji povečala odpornost Escherichia coli in Staphylococcus aureus na enrofloksacin.
• Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance. 
• uporaba zdravila, ki ni v skladu z navodili iz povzetka glavnih značilnosti zdravila, lahko poveča razširjenost bakterij, ki so odporne na fluorokinolone, in lahko zaradi možnosti navzkrižne odpornosti zmanjša učinkovitost zdravljenja z drugimi kinoloni.
• prudent use warnings for fluoroquinolones were recommended by the CVMP for the products concerned and should be strictly followed; 
• je odbor CVMP za vsa zadevna zdravila priporočil opozorila o preudarni uporabi fluorokinolonov, ki jih je treba strogo upoštevati;
The dosage is 10 mg enrofloxacin per kg bodyweight (bw) during 5 days. 
Odmerek je 10 mg enrofloksacina na kilogram telesne mase v 5 dneh.
The conclusion of a comparative study of plasma levels of enrofloxacin and its metabolite ciprofloxacin during treatment with the product at doses equivalent to 5 and 10 mg/kg bw of enrofloxacin administered in drinking water for 5 consecutive days was that the effective dose regimen of enrofloxacin for the treatment of respiratory infections caused by P. multocida in rabbits is 10 mg/kg bw. 
Ugotovitev primerjalne študije ravni enrofloksacina in njegovega metabolita ciprofloksacina v plazmi med zdravljenjem z zdravilom v odmerkih 5 in 10 mg enrofloksacina/kg telesne mase, ki so se 5 zaporednih dni dajali s pitno vodo, je bila, da je učinkoviti odmerek enrofloksacina za zdravljenje okužb dihal pri kuncih, ki jih povzroča P. multocida, 10 mg/kg telesne mase.
The CVMP was requested to give its opinion as to whether the benefit-risk ratio for HIPRALONA ENRO-S and its generics is positive when the products are administered to rabbits and whether the introduction of such highly critical antibiotics in a food production species, used via oral route, is in line with the current recommendations to implement prudent use of antimicrobials (EMEA/CVMP/SAGAM/184651/2005)1. 
CVMP je bil zaprošen za mnenje o tem, ali je razmerje med koristmi in tveganji zdravila HIPRALONA ENRO-S in njegovih generičnih zdravil pozitivno, kadar se ta dajejo kuncem, ter ali je uvajanje takih bistveno pomembnih antibiotikov pri živalskih vrstah za proizvodnjo živil po peroralni poti skladno s trenutnimi priporočili za preudarno uporabo protimikrobnih zdravil (EMEA/CVMP/SAGAM/184651/2005)1.
Overall benefit-risk 
Splošno razmerje med koristmi in tveganji
Overall summary of the scientific evaluation of HIPRALONA ENRO-S and its generics intended for use in rabbits (see Annex I) 
Splošni povzetek znanstvenega vrednotenja zdravila HIPRALONA ENRO-S in njegovih generičnih zdravil, namenjenih uporabi pri kuncih (glejte Prilogo I)
HIPRALONA ENRO-S and its generics contain 100 mg enrofloxacin per ml oral solution for use in drinking water. 
Zdravilo HIPRALONA ENRO-S in njegova generična zdravila vsebujejo 100 mg enrofloksacina na ml peroralne raztopine za uporabo v pitni vodi.
RESAPATH annual reports to reach a conclusion on the trends of resistance to enrofloxacin in E. coli in rabbits compared to other resistance studies provided. 
Žal pa ni na voljo dovolj podatkov o merilih za razlago, ki so bila uporabljena v letnih poročilih mreže RESAPATH, da bi prišli do zaključka v zvezi s trendi odpornosti E. coli na enrofloksacin pri kuncih v primerjavi z drugimi predloženimi študijami odpornosti.
Therefore it could be considered that the use of enrofloxacin in rabbits should not significantly increase overall use of enrofloxacin in the EU when compared to its use in other animal species. 
Zato je mogoče šteti, da uporaba enrofloksacina pri kuncih v primerjavi z uporabo te zdravilne učinkovine pri drugih živalskih vrstah ne bo bistveno povečala splošne uporabe enrofloksacina v EU.
Most of the MICs obtained were above the range expected for wild-type isolates, data from EUCAST (European Committee on Antimicrobial Susceptibility Testing) indicate that the distribution of MICs of enrofloxacin for the wild type of the target pathogen, P. multocida, is between 0.004 and 0.03 µg/ml. 
Podatki odbora EUCAST (European Committee on Antimicrobial Susceptibility Testing - Evropski odbor za preskušanje protimikrobne občutljivosti) kažejo, da je razporeditev vrednosti MIC za enrofloksacin pri divjem tipu ciljnega patogena, P. multocida, med 0,004 in 0,03 µg/ml.
Capsanes, 12 - Polígono Agro-Reus E-43206 - REUS (Tarragona) SPAIN 
Capsanes, 12 - Polígono Agro-Reus E-43206 - REUS (Tarragona) ŠPANIJA
• the CVMP considered whether the benefit-risk ratio for HIPRALONA ENRO-S and its generics is positive when the products are administered to rabbits and whether the use of such highly critical antibiotics in a food producing species, used via oral route, is in line with the current recommendations to implement responsible use of antimicrobials. 
• je odbor CVMP presodil, ali je razmerje med koristmi in tveganji zdravila HIPRALONA ENRO-S in njegovih generičnih zdravil pozitivno, kadar se ta dajejo kuncem, ter ali je uvajanje takih bistveno pomembnih antibiotikov pri živalskih vrstah za proizvodnjo živil po peroralni poti skladno s trenutnimi priporočili za odgovorno uporabo protimikrobnih zdravil;
K-Flox 100mg/ml Πόσιμο διάλυμα για ορνίθια κρεοπαραγωγής και κουνέλια 
K-Flox 100mg/ml Πόσιμο διάλυμα για ορνίθια κρεοπαραγωγής και κουνέλια piščanci (pitovni), kunci
Global Vet Health, SL Capcanes, 12 bajos Poligono Agro-Reus 43206 Reus SPAIN 
Global Vet Health, SL Capcanes, 12 bajos Poligono Agro-Reus 43206 Reus ŠPANIJA
In order to confirm the adequate dose for rabbits two studies were carried out showing that the optimal dose for the treatment of respiratory infections caused by P. multocida in rabbits is 10 mg/kg bw for 5 consecutive days. 
Da bi potrdili ustrezen odmerek za kunce, sta bili opravljeni dve študiji, ki sta pokazali, da je najprimernejši odmerek za zdravljenje okužb dihal pri kuncih, ki jih povzroča P. multocida, 10 mg/kg telesne mase 5 zaporednih dni.
Sociedade Distr. 
Portugalska VETLIMA Sociedade Distr.
Whereas 
Ker:
The route of administration for pigs is injectable or oral. 
Prašičem se zdravilo injicira ali daje peroralno.
Veterinary Research, 42:44 - http://www.veterinaryresearch.org/content/42/1/44/#ins1 6 EMA document on Trends in the sales of veterinary antimicrobial agents in nine European countries (2005-2009)' 
6 EMA document on Trends in the sales of veterinary antimicrobial agents in nine European countries (2005-2009)'
HIPRALONA ENRO-S, and its generics, contain enrofloxacin as active ingredient, and are indicated in rabbits for the treatment of respiratory infections due to Pasteurella multocida. 
Zdravilo HIPRALONA ENRO-S in njegova generična zdravila vsebujejo zdravilno učinkovino enrofloksacin in so indicirana pri kuncih za zdravljenje okužb dihal, ki jih povzroča Pasteurella multocida.
The indication for rabbits is the treatment of respiratory diseases due to P. multocida strains susceptible to enrofloxacin. 
Pri kuncih so indicirana za zdravljenje bolezni dihal, ki jih povzročijo sevi P. multocida, občutljivi za enrofloksacin.
The conclusion of this study was that the optimal dose for the treatment of respiratory infections caused by P. multocida in rabbits is 10 mg/kg bw for 5 consecutive days. 
V tej študiji je bilo ugotovljeno, da je najprimernejši odmerek za zdravljenje okužb dihal pri kuncih, ki jih povzroča P. multocida, 10 mg/kg telesne mase 5 zaporednih dni.
Poligono Agro-Reus 43206 Reus SPAIN 
Poligono Agro-Reus 43206 Reus ŠPANIJA
The route of administration for rabbits is oral via drinking water, similar to the route of administration for poultry. 
Pri kuncih se zdravilo daje peroralno s pitno vodo, podobno kot pri perutnini.
7 CVMP Reflection paper on the use of fluoroquinolones in food- producing animals - Precautions for use in the SPC regarding prudent use guidance (EMEA/CVMP/416168/2006)http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500005173.pdf that are less likely to produce resistances of public health concern are used as a first option instead of fluoroquinolones. 
7 Presoja odbora CVMP o uporabi fluorokinolonov pri živalih za proizvodnjo živil - Smernice za previdnostne ukrepe v povzetku glavnih značilnosti zdravila glede preudarne uporabe (EMEA/CVMP/416168/2006)http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500005173.pdf.
Enrofloxacin 100 mg Oral solution Chickens (Broilers, replacement chickens, broiler breeders) and rabbits 
Enrofloxacin 100 mg peroralna raztopina piščanci (pitovni, nesnice, rejenci pitovnih piščancev) in kunci
• the CVMP considered that the overall benefit-risk balance is positive for the products concerned by this procedure; the CVMP recommended the maintenance of the marketing authorisations for the veterinary medicinal product HIPRALONA ENRO-S and its generics (see Annex I) in accordance with the previously approved product information. 
je CVMP priporočil ohranitev dovoljenj za promet z zdravilom HIPRALONA ENRO-S in njegovimi generičnimi zdravili za uporabo v veterinarski medicini (glejte Prilogo I) v skladu s predhodno odobrenimi informacijami o zdravilu.
A et al2, 2006, Belloc et al3, 2005, Lurette A. et al4, 2009, Mathieu. 
Prenos horizontalne in vertikalne odpornosti pri perutnini in prašičih se je preučeval ob upoštevanju posebnih značilnosti posamezne vrste reje živali (Petersen, A., in drugi2, 2006, Belloc in drugi3, 2005, Lurette, A., in drugi4, 2009, Mathieu, A.5, 2011).
Oral solution Poultry (Chicken and Turkeys), 
perutnina (piščanci in purani), kunci
Enrofloxacin 100 mg Oral solution Chickens (broilers), 
Enrofloxacin 100 mg peroralna raztopina piščanci (pitovni), kunci
Date of first authorisation: 3 October 2011 Date of latest renewal: 9 June 2016 
Datum prve odobritve: 03. oktober 2011 Datum zadnjega podaljšanja: 9. junij 2016
Some side effects can be serious and need immediate medical attention: 
Nekateri neželeni učinki so lahko resni in je potrebna takojšnja zdravniška pomoč:
• Second and third trimester of pregnancy (see sections 4.4 and 4.6) 
• drugo ali tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6)
* The event may have happened by chance or could be related to a mechanism currently not known. 
* Lahko gre za naključno dogajanje ali pa je lahko povezano s trenutno še neznanim mehanizmom delovanja.
Possible side effects of telmisartan: 
Možni neželeni učinki telmisartana:
Do not take a double dose to make up for forgotten individual doses. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti posamezni odmerek.
- if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6). 
- če ste alergični na telmisartan ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Your doctor will normally advise you to stop taking Telmisartan Teva Pharma before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Telmisartan Teva Pharma. 
Zdravnik vam bo praviloma svetoval, da zdravilo Telmisartan Teva Pharma prenehate jemati, preden boste zanosili ali takoj, ko boste vedeli, da ste noseči, in vam svetoval, da namesto zdravila Telmisartan Teva Pharma jemljete drugo zdravilo.
very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to 
zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000).
Biotransformation 
l. Biotransformacija
If you have the impression that the effect of Telmisartan Teva Pharma is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila Telmisartan Teva Pharma premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
The mean steady state apparent volume of distribution (Vdss) is approximately 500 l. 
Povprečen navidezni porazdelitveni volumen v stanju dinamičnega ravnovesja (Vdss) je približno 500
- if you are more than 3 months pregnant (It is also better to avoid Telmisartan Teva Pharma in early pregnancy - see pregnancy section). 
- če ste noseči več kot 3 mesece (zdravilu Telmisartan Teva Pharma se je bolje izogibati v zgodnji nosečnosti - glejte poglavje o nosečnosti).
Eastbourne, East Sussex, BN22 9AG United Kingdom 
East Sussex, BN22 9AG Velika Britanija
See also information under the heading “Do not take Telmisartan Teva Pharma”. 
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Telmisartan Teva Pharma”.
There are no adequate data from the use of Telmisartan Teva Pharma in pregnant women. 
Ni zadostnih podatkov o uporabi zdravila Telmisartan Teva Pharma pri nosečnicah.